The goal of these analyses was to assess tumor tissue from patients enrolled in ABRAZO, with a focus on BRCA1/2mut, including germline-tumor concordance and zygosity; other genes implicated in homologous recombination DNA damage repair (DDR); other commonly mutated non-DDR genes; homologous recombination deficiency (HRD), assessed using genome-wide LOH (gLOH); and to explore potential correlations of the above with efficacy outcomes. Here, BRCA1 is linked to neoplasm.